T-DM1-related telangiectasias: a potential role in secondary bleeding events.
Department of Dermatology and Clinical Research Unit; sibaud.vincent@iuct-oncopole.fr.
V
V
Sibaud
Oral Medicine, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole;
E
E
Vigarios
Department of Dermatology, Institut Leon Berard, Lyon;
P
P
Combemale
Department of Pathology, Institut Universitaire du Cancer, Toulouse Oncopole, France;
L
L
Lamant
Dermatology Service, Memorial Sloan Kettering Cancer Center, New York, USA;
M E
ME
Lacouture
Department of Oncology and Clinical Research Unit, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France.
J L
JL
Lacaze
Department of Oncology and Clinical Research Unit, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France.
F
F
Dalenc
Department of Oncology and Clinical Research Unit, Institut Claudius Regaud, Institut Universitaire du Cancer, Toulouse Oncopole, France.
J P
JP
Delord
D000080044:Ado-Trastuzumab Emtansine; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D008453:Maytansine / Q000009:adverse effects / Q000031:analogs & derivatives*; D013684:Telangiectasis / Q000139:chemically induced*; D000068878:Trastuzumab
D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine